What is Iovance Lifileucel for Advanced Melanoma?

Lifileucel, sold under the brand name Amtagvi, is a one-time cell therapy made from a patient’s own immune cells that have already infiltrated their tumor. On February 16, 2024, the FDA granted it accelerated approval for adults with advanced melanoma that has progressed after other immunotherapies, making it the first tumor-derived T-cell therapy ever approved in the United States.¹ The therapy occupies a unique niche: it is designed specifically for people whose melanoma has stopped responding to the checkpoint inhibitors and targeted drugs that have transformed treatment over the past decade.

How TIL Therapy Works and Why It Matters for Solid Tumors

Your immune system already sends T cells to attack cancer, and some of those T cells manage to burrow into the tumor itself. These are tumor-infiltrating lymphocytes, or TILs. The problem is that most tumors suppress those T cells or simply outnumber them. Lifileucel flips the odds by harvesting those TILs from a piece of surgically removed tumor, expanding them into billions of cells in a laboratory, and then infusing them back into the patient’s bloodstream in vastly larger numbers than the body could produce on its own.²

What sets TIL therapy apart from other cell-based cancer treatments is polyclonality. CAR T cells, which have been successful in blood cancers, are genetically engineered to recognize one or occasionally two targets on cancer cells. TILs, by contrast, are a diverse mix of T cells carrying many different receptors, each trained on a different feature of the tumor they came from. That diversity lets them attack the cancer on multiple fronts at once, which is a meaningful advantage in solid tumors where cancer cells within the same mass can look quite different from one another.³ If one set of cancer cells manages to dodge one type of T cell, other TILs in the infusion may still recognize and kill them. That built-in redundancy reduces the chances of the tumor escaping treatment altogether.

Who Is Eligible

The approval is narrow by design. Lifileucel is indicated for adults whose melanoma cannot be surgically removed or has spread to other parts of the body, and who have already received at least one course of a PD-1-blocking antibody. If the patient carries a BRAF V600 mutation, they must also have tried a BRAF inhibitor, with or without an MEK inhibitor, before becoming eligible.⁴ In practical terms, these are patients who have exhausted the standard options that work for the majority of people with advanced melanoma and whose disease continues to progress.

One important biological detail underpins why this therapy still works in people whose cancer resisted checkpoint inhibitors: the mechanisms of resistance appear to be at least partially independent. Research has shown that TIL therapy can produce clinical responses even in patients whose tumors became refractory to anti-PD-1 drugs, suggesting that the two treatment approaches rely on overlapping but distinct pathways to kill cancer cells.⁵ A patient whose cancer learned to evade a checkpoint inhibitor has not necessarily learned to evade a massive army of freshly expanded TILs.

What the Treatment Process Looks Like

Lifileucel is a one-time infusion, but the process surrounding it is intensive and stretches over weeks. It begins with surgery. A surgeon removes a piece of the patient’s tumor, typically a specimen roughly 1.5 to 4 centimeters in diameter, taking care to trim away necrotic and fatty tissue that would impair TIL growth in the lab.⁶ Tissue quality matters: specimens with a lot of dead or fatty areas yield fewer usable TILs.⁷

The harvested tissue is shipped to a manufacturing facility, where TILs are isolated and expanded over several weeks. While the patient waits for their personalized product to be manufactured, they may receive bridging therapy to keep the cancer from progressing too aggressively. Once the TILs are ready, the patient is admitted to the hospital for the most demanding phase of treatment.

Before the cells go in, the patient undergoes lymphodepleting chemotherapy. The standard regimen uses cyclophosphamide for two days followed by fludarabine for five days.⁸ This conditioning step is not optional: by depleting the patient’s existing immune cells, it creates space for the infused TILs to engraft and multiply without competition from regulatory T cells that would otherwise suppress them.

After the TIL infusion, patients receive up to six doses of high-dose interleukin-2, an immune-stimulating protein that helps the newly infused cells survive and continue expanding inside the body. Each dose is given every eight to twelve hours over two to three days.⁹ Patients are still severely immune-suppressed from the chemotherapy at this point, so fevers and other complications need close monitoring. Expert consensus guidelines note that missed or truncated courses of interleukin-2 do not appear to harm outcomes, which gives clinical teams some flexibility when patients become too sick to tolerate additional doses.⁹

Hospital stays typically last around two weeks after the TIL infusion, during which the care team monitors for hematological recovery and resolution of interleukin-2 side effects.¹⁰

How Well It Works

The pivotal trial behind the approval, called C-144-01, enrolled patients who had already failed prior immunotherapy and, where applicable, targeted therapy. At a five-year follow-up, roughly 31% of patients had an objective response, meaning their tumors shrank enough to meet formal criteria. About 6% had a complete response, where detectable disease disappeared entirely, and about 26% had a partial response. Altogether, nearly 80% of patients experienced some reduction in tumor size, even if it did not meet the threshold for a formal response.¹¹

The durability of those responses is where the data gets genuinely interesting. Among patients who responded, the median duration of response was over three years. Some responses deepened over time: four patients whose tumors initially shrank partially went on to achieve a complete response more than a year after the infusion. At the five-year mark, about 31% of responders still had ongoing responses.¹¹ For a population that had run out of approved treatment options, those numbers represent a meaningful fraction of patients getting durable benefit from a single treatment.

It is worth framing these results honestly: a 31% response rate means that roughly two out of three patients did not experience a formal response. This is not a cure-all. But the patients enrolled in this trial had disease that had already resisted the most effective drugs available, and the fact that a third of them responded, some for years, is what convinced the FDA to grant accelerated approval while longer-term confirmatory studies continue.

Side Effects and Safety Concerns

The side-effect profile of lifileucel is dominated not by the TIL cells themselves but by the conditioning chemotherapy and the interleukin-2 that bookend the infusion. The lymphodepleting chemotherapy causes prolonged and severe suppression of blood cell counts. A meta-analysis covering TIL therapy with high-dose interleukin-2 across 12 studies and 670 patients found that febrile neutropenia, where the patient develops a fever while their white blood cell count is dangerously low, occurred in about 60% of cases.¹² Serious infections occurred in roughly 8% of patients, and severe immune-related reactions were seen in about 4%.¹²

Fatal adverse events are rare. Across the pooled data in that meta-analysis, nine deaths were reported, and most were attributed either to the conditioning regimen or were considered unrelated to the treatment itself. Patients who go through this therapy need to be fit enough to tolerate what amounts to a short course of intense chemotherapy followed by a potent immune stimulant, all while their immune system is temporarily wiped out. Treating centers screen patients carefully, and the therapy is only administered at specialized facilities equipped for cellular therapy and the kind of intensive supportive care required during recovery.

Manufacturing Logistics and Timing Challenges

Because each dose of lifileucel is made from an individual patient’s own tumor, manufacturing is personalized and cannot be stockpiled. The process from tumor collection to delivery of the finished product takes weeks. In the real world, coordinating surgery, lab processing, and scheduling a manufacturing slot with the manufacturer adds further time. Early real-world experience at one center found that the average interval from initial referral to actual TIL infusion was about 128 days.

That center implemented a quality-improvement workflow where a cellular therapy nurse served as a single point of contact, coordinating all steps from surgical scheduling through manufacturing slot allocation. The change reduced the referral-to-infusion interval to about 96 days and cut the time from referral to initial consultation nearly in half.¹³ Those numbers highlight a real tension in this therapy: the patients who need it have aggressive, progressing cancer, but the treatment itself requires a multi-month manufacturing window. Bridging therapy during the wait is common, and not all patients remain eligible by the time their TILs are ready.

The surgical procurement step also introduces variability. Not every tumor yields tissue of sufficient quality. Fat, necrosis, and poor vascularity in the resected specimen can reduce TIL growth in the lab.⁷ Expert guidelines recommend that surgeons aim for a specimen at least 1.5 centimeters across and carefully trim any non-viable tissue before shipping.⁶ Manufacturing failure, where the lab cannot grow enough TILs from the tissue provided, is an acknowledged risk, though the pivotal trial’s manufacturing success rate was high enough to support approval.

Cost and Access

Lifileucel carries a list price of roughly $515,000 for the cell product alone, and total treatment costs run substantially higher once you factor in the surgical procurement, hospital admission, chemotherapy, interleukin-2, and supportive care. Whether that represents reasonable value for money is a live debate. An economic analysis modeled in a middle-income European country found that lifileucel was not cost-effective compared to chemotherapy or triple-combination immunotherapy at conventional willingness-to-pay thresholds, with incremental cost-effectiveness ratios far exceeding the highest acceptable threshold for that country.¹⁴

Earlier modeling work examining TIL therapy more broadly suggested that cost-effectiveness depends heavily on how much the manufacturing itself costs. At academic-center production prices, TIL therapy could plausibly be cost-effective. But at commercial pricing levels, where manufacturing costs are estimated to be at least three times higher, the probability of cost-effectiveness drops to essentially zero at commonly used willingness-to-pay thresholds.¹⁵ The economics could shift as manufacturing scales up, competition enters the space, and real-world outcomes data clarify how durable responses translate into survival gains. For now, access is limited to specialized centers, and insurance coverage varies.

Gene-Edited TILs and the Next Generation

Lifileucel uses unmodified TILs: the cells are expanded in the lab but not genetically altered. Researchers are already working on the next step, which involves editing TILs before they go back into the patient. The most prominent approach targets PD-1, a receptor on T cells that tumors exploit to shut down immune attack. By using CRISPR gene-editing technology to knock out the gene for PD-1 on TILs before expansion, researchers aim to create T cells that are resistant to one of the tumor’s main defense mechanisms.

Early preclinical work has been encouraging. In laboratory and animal studies, PD-1-knockout TILs showed superior tumor control compared to unmodified TILs, and the editing process did not meaningfully impair the cells’ ability to expand during manufacturing.¹⁶ Separate preclinical manufacturing runs demonstrated that PD-1-knockout TILs could be produced at clinical scale with acceptable purity and cell counts, and in mouse models these edited cells controlled tumors significantly better than unedited TILs or unedited TILs combined with anti-PD-1 antibody treatment.¹⁷

These approaches are still in early clinical testing and years away from approval, but they hint at a future where TIL therapy could be made more potent without requiring additional systemic drugs. There is also active research into extending TIL therapy beyond melanoma entirely. The polyclonal nature of TILs makes them theoretically attractive for other solid tumors, and early-phase trials have begun in cancers of the lung, cervix, head and neck, and colon. Melanoma was the proving ground because it tends to be highly immunogenic and generates abundant TILs, but the broader applicability of the approach is the real prize the field is chasing.

How Lifileucel Fits into the Broader Melanoma Treatment Landscape

Advanced melanoma treatment has been transformed over the past fifteen years by checkpoint inhibitors and targeted therapies, and the majority of patients now receive those drugs first. Lifileucel enters the picture only after those frontline options have failed. It is not competing with checkpoint inhibitors for first-line use; it exists because a sizable minority of patients develop resistance to those drugs and need something fundamentally different.

For those patients, the alternatives before lifileucel’s approval were limited. Options typically included clinical trials, chemotherapy with low response rates, or second-line immunotherapy combinations that worked for some but far from all. Lifileucel offers a mechanistically distinct option, one that leverages the tumor’s own immune infiltrate rather than trying to release the brakes on a systemic immune response that has already proven insufficient. The evidence that TIL therapy works through at least partially independent mechanisms from checkpoint inhibitors is what gives it clinical rationale in the post-checkpoint population.⁵

Whether lifileucel eventually moves earlier in the treatment sequence, perhaps alongside checkpoint inhibitors rather than after they fail, is a question that ongoing clinical trials may answer. For now, its role is defined by its approval label: a treatment for people who have already tried and progressed on the best available therapies and who are well enough to tolerate the conditioning regimen and hospital stay the treatment demands.